159 related articles for article (PubMed ID: 12182054)
1. [Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine].
Jastrzebska H; Gietka-Czernel M; Zgliczyński S
Wiad Lek; 2001; 54 Suppl 1():383-8. PubMed ID: 12182054
[TBL] [Abstract][Full Text] [Related]
2. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
4. [Treatment with L-thyroxine for differentiated thyroid carcinoma].
Łacka K
Wiad Lek; 2001; 54 Suppl 1():368-72. PubMed ID: 12182051
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of effects of L-thyroxine therapy in differentiated thyroid carcinoma on the cardiovascular system --prospective study].
Matuszewska G; Roskosz J; Włoch J; Jurecka-Tuleja B; Hasse-Lazar K; Kowalczyk P; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():373-7. PubMed ID: 12182052
[TBL] [Abstract][Full Text] [Related]
7. [Hormone replacement in patients with carcinoma of the thyroid (author's transl)].
Creutzig H; Kallfelz I; Haindl H; Schulle R; Hundeshagen H
Dtsch Med Wochenschr; 1977 Dec; 102(48):1763-6. PubMed ID: 411647
[TBL] [Abstract][Full Text] [Related]
8. Thyroid function and postmenopause.
Schindler AE
Gynecol Endocrinol; 2003 Feb; 17(1):79-85. PubMed ID: 12724022
[TBL] [Abstract][Full Text] [Related]
9. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
[TBL] [Abstract][Full Text] [Related]
10. [Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma].
Miyakawa M
Nihon Rinsho; 2007 Nov; 65(11):2073-7. PubMed ID: 18018573
[TBL] [Abstract][Full Text] [Related]
11. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
12. [Pregnancy in women with thyroid cancer treated with suppressive doses of L-thyroxine].
Jastrzebska H; Gietka-Czernel M; Zgliczyński S; Czech W; Lewartowska A; Debski R
Wiad Lek; 2001; 54 Suppl 1():389-97. PubMed ID: 12182055
[TBL] [Abstract][Full Text] [Related]
13. Glucose tolerance and lipid profile in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trial.
Heemstra KA; Smit JW; Eustatia-Rutten CF; Heijboer AC; Frölich M; Romijn JA; Corssmit EP
Clin Endocrinol (Oxf); 2006 Dec; 65(6):737-44. PubMed ID: 17121524
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of reliable pituitary suppression therapy through varying thyroid hormone dosage following total thyroidectomy due to a differentiated thyroid carcinoma].
Wahl R; Hüfner M; Röher HD; Papke W
Langenbecks Arch Chir; 1975; Suppl():469-74. PubMed ID: 1207280
[TBL] [Abstract][Full Text] [Related]
15. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
Khmara IM; Tolkachev IuV
Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
[TBL] [Abstract][Full Text] [Related]
16. Short-term overt hypothyroidism induces discrete diastolic dysfunction in patients treated for differentiated thyroid carcinoma.
Hoftijzer HC; Bax JJ; Heemstra KA; Bleeker GB; Delgado V; van der Klaauw AA; Romijn JA; Smit JW; Corssmit EP
Eur J Clin Invest; 2009 Mar; 39(3):204-10. PubMed ID: 19260950
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
[TBL] [Abstract][Full Text] [Related]
18. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
19. Thyroid dysfunction in perimenopausal and postmenopausal women.
Pearce EN
Menopause Int; 2007 Mar; 13(1):8-13. PubMed ID: 17448261
[TBL] [Abstract][Full Text] [Related]
20. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
